Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 19, Issue 4, 2001, Pages 1071-1077

  Isla, D ^a   Rosell, R ^a   Sanchez J J ^a   Carrato, A ^a   Felip, E ^a   Camps, C ^a   Artal, A ^a   Gonzalez Larriba J L ^a   Azagra, P ^a   Alberola, V ^a   Martin, C ^a   Massuti B ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEUROTOXICITY; PRIORITY JOURNAL;

EID: 0035865303     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.4.1071     Document Type: Article

References (36)

1. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: Effects on survival and quality of life
2. Chemotherapy in non-small-cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials
3. Survival determinants in extensive-stage non-small-cell lung cancer: The Southwest Oncology Group experience
4. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer
5. Single agent versus combination chemotherapy in patients with advanced nonsmall cell lung carcinoma. A meta-analysis of response, toxicity, and survival
6. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer
7. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project
8. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer
9. A phase I trial of gemcitabine plus paclitaxel combination therapy in patients with refractory solid tumors
10. Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in chemo-naïve patients with advanced non-small-cell lung cancer
11. A phase I-II study of gemcitabine and paclitaxel in advanced non-small-cell lung cancer patients
12. Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors
13. A phase I trial of gemcitabine and paclitaxel in patients with recurrent epithelial ovarian cancer
14. A phase I study to investigate alternate sequencing of the combination of gemcitabine and paclitaxel in ovarian carcinoma
15. Toxicity and response criteria of the Eastern Cooperative Oncology Group
16. Reporting results of cancer treatment
17. New guidelines to evaluate the response to treatment in solid tumors
18. Nonparametric estimation from incomplete observations
19. Docetaxel (Taxotere) and gemcitabine in combination therapy
20. A phase I/II study of paclitaxel and gemcitabine in patients with advanced non small cell lung cancer
21. Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies
22. Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: A multicenter phase II trial
23. Phase I/II trial of paclitaxel by 1-hour infusion, carboplatin, and gemcitabine in the treatment of patients with advanced nonsmall cell lung carcinoma
24. Paclitaxel, gemcitabine and cisplatin in non-resectable non-small-cell lung cancer
25. New chemotherapeutic agents prolong survival and improve quality of life in non-small-cell lung cancer: A review of the literature and future directions
26. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients
27. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer
28. Amifostine, cisplatin, and vinblastine in metastatic non-small-cell lung cancer: A report of high response rates and prolonged survival
29. E1594: A randomized phase III trial in metastatic non-small-cell lung cancer (NSCLC) - Outcome of PS 2 patients (Pts). An Eastern Cooperative Group trial (ECOG)
30. A randomized phase III trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cisplatin (VC) in untreated advanced non-small-cell lung cancer (NSCLC): A Southwest Oncology Group (SWOG) trial
31. 2) plus carboplatin (6AUC) in advanced non-small-cell lung cancer (NSCLC): A multicenter randomized trial
32. A phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small-cell lung cancer
33. Docetaxel plus cisplatin versus gemcitabine chemotherapy in advanced non-small-cell lung cancer: A preliminary analysis of a multicenter randomized phase II trial
34. Combination chemotherapy with paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in inoperable non-small-cell lung cancer: A phase III randomized study - Preliminary results
35. A randomized phase III trial of paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in advanced non-small-cell lung cancer (NSCLC): A preliminary analysis